全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Pulmonary Adenocarcinoma Occurring 5 Years after Resection of a Primary Pancreatic Adenocarcinoma: A Relevant Differential Diagnosis

DOI: 10.1155/2014/841907

Full-Text   Cite this paper   Add to My Lib

Abstract:

Ductal adenocarcinoma of the pancreas is a lethal disease. Surgical extirpation only offers the slim chance for long-term survival in localized disease. We report on a 73 year old female patient who initially underwent successful resection of pancreatic adenocarcinoma in May 2005. She was treated with adjuvant chemotherapy with gemcitabine. In October 2010 the patient noticed increasing dyspnea with haemoptysis. She was soon referred to our center. After the diagnosis of pulmonary adenocarcinoma with widespread metastasis, she was treated with systemic chemotherapy. For a period of next three years, she was treated with different chemotherapy regimens due to repeated episodes of tumor progression. To the best of our knowledge after reviewing the literature, this case represents an unusually clinical course with metachronous pulmonary adenocarcinoma arising after treatment of a primary pancreatic cancer after a long latency period. 1. Main Article The patient had undergone distal pancreatectomy with portal vein resection for pancreatic body cancer in early May 2005. At the time of pancreatectomy, the cancer was confined to the organ and had not invaded the portal-splenic vein junction. To ensure an adequate surgical margin, subtotal distal pancreatectomy was performed. Histopathological examination revealed an invasive well-differentiated ductal adenocarcinoma of the pancreas. Adjuvant chemotherapy with gemcitabine was administered. All follow-up reevaluations showed no signs of tumor recurrence, and external laboratory tests did not show elevated CA 19-9 levels. In October 2010, she was referred to our center due to the increasing dyspnea with haemoptysis. Contrast-enhanced tomography revealed a major pulmonary mass in the right upper lobe with contralateral metastases (Figure 1(a)). Macroscopic histologic workup revealed tumor nodule measured 1.3?cm in maximum diameter and it was sharply demarcated. Histological examination revealed a well-differentiated adenocarcinoma with lepidic, papillary, and acinar growth patterns and intracellular and extracellular mucin production. A curative tumor resection was not feasible. First line systemic chemotherapy with carboplatin and pemetrexed was initiated. After five months, stable disease was achieved (Figure 1(b)). Figure 1: Contrast-enhanced tomography revealed a major pulmonary mass within the right upper lobe (arrow) (a). Stable disease was achieved under first line therapy with carboplatin and pemetrexed (b). CT-evaluation revealed tumor progression of the pulmonary mass and metastases, huge pleural

References

[1]  R. E. Schwarz, P. G. Chu, and F. W. Grannis Jr., “Pancreatic tumors in patients with lung malignancies: A spectrum of clinicopathologic considerations,” Southern Medical Journal, vol. 97, no. 9, pp. 811–815, 2004.
[2]  S. C. Mayo, H. Nathan, J. L. Cameron, et al., “Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent,” Cancer, vol. 118, no. 10, pp. 2674–2681.
[3]  K. C. Conlon, D. S. Klimstra, and M. F. Brennan, “Long-term survival after curative resection for pancreatic ductal adenocarcinoma: Clinicopathologic analysis of 5-year survivors,” Annals of Surgery, vol. 223, no. 3, pp. 273–279, 1996.
[4]  S. Emoto, H. Kamachi, M. Tahara, et al., “A case of lung metastasis occurring 6 years after pancreaticoduodenectomy for pancreas cancer,” Journal of Japan Surgical Association, vol. 71, no. 4, pp. 1034–1038, 2010.
[5]  C. Sperti, C. Pasquali, A. Piccoli, and S. Pedrazzoli, “Recurrence after resection for ductal adenocarcinoma of the pancreas,” World Journal of Surgery, vol. 21, no. 2, pp. 195–200, 1997.
[6]  M. H. Katz, H. Wang, J. B. Fleming et al., “Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma,” Annals of Surgical Oncology, vol. 16, no. 4, pp. 836–847, 2009.
[7]  L. Faloppi, K. Andrikou, and S. Cascinu, “Cetuximab : still an option in the treatment of pancreatic cancer?” Expert Opinion on Biological Therapy, vol. 13, no. 5, pp. 791–801, 2013.
[8]  R. Gervais, G. Robinet, C. Clement- Duchene, et al., “Pemetrexed and carboplatin, an active option in first- line treatment of elderly patients with advanced non- small cell lung cancer (NSCLC): a phase II trial,” Lung Cancer, vol. 80, no. 2, pp. 185–190, 2013.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413